We next sought to investigate the ability of BIM SAHBA to release endogenous BIM from BCL-2 or MCL-1 in DLBCL that were sensitive (OCI-Ly1 > SU-DHL-6 > OCI-Ly8) or resistant (SU-DHL-5) to ABT-737 (Figure 1A, Supplementary Table 1) [10, 11]. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.